14-acetyl-7,13,19-trihydroxy-5,10,16,21-tetramethoxy-13-methylhexacyclo[13.8.0.0²,¹¹.0³,⁸.0⁴,²².0¹⁸,²³]tricosa-1,3,5,7,10,15,18(23),19,21-nonaene-9,17-dione;hypocrellin A;Hypocrellin;shiraiachrome A
Method for reduction of autofluorescence from biological samples
申请人:Leica Microsystems CMS GmbH
公开号:US11415516B2
公开(公告)日:2022-08-16
The invention discloses a method for reduction of autofluorescence in biological samples, comprising the steps of:
a) providing a biological microscopy sample;
b) irradiating the sample with visible light, wherein the visible light has a spectrum such that at least 50% of the light intensity emanates from a narrow wavelength interval within the visible range. The invention also discloses a method for autofluorescence reduction with triplet sensitizers irradiated with visible light.
本发明公开了一种减少生物样品中自发荧光的方法,包括以下步骤:
a) 提供生物显微镜样本;
b) 用可见光照射样品,其中可见光的光谱使得至少 50%的光强来自可见光范围内的窄波长区间。本发明还公开了一种用可见光照射三重敏化剂减少自发荧光的方法。
Spectroscopic studies on the interaction of Ga3+-hypocrellin A with myoglobin
In this article, the interaction mechanism of Ga3+-hypocrellin A (Ga3+-EA) with myoglobin (Mb) is studied in detail through various spectroscopic technologies. UV-vis absorption and fluorescence spectra demonstrate the interaction process. The Stern-Volmer plot and the time-resolved fluorescence study suggest the fluorescence quenching mechanism of Mb by Ga3+-HA is a static quenching procedure, and the electronic transfer forces play a major role in binding Ga3+-HA to Mb. Furthermore, synchronous fluorescence studies and circular dichroism (CD) spectra reveal that the conformation of Mb is changed after its conjugation with Ga3+-HA. (C) 2013 Elsevier B.V. All rights reserved.
Excited-State Intramolecular H Atom Transfer of Hypericin and Hypocrellin A Investigated by Fluorescence Upconversion
作者:A. V. Smirnov、K. Das、D. S. English、Z. Wan、G. A. Kraus、J. W. Petrich
DOI:10.1021/jp992436a
日期:1999.10.1
The excited-state intramolecular H atom transfer reaction occurring in hypericin and hypocrellin A is investigated by means of the fluorescence upconversion technique in a variety of solvents. Rising components of similar to 10 ps, attributable to intramolecular H atom transfer, are Clearly observed in the fluorescence upconversion traces of both hypericin and hypocrellin A. The amplitude of the rising component is emission wavelength dependent and occurs on the blue edge of the emission spectra. Neither in hypericin nor in hypocrellin A does this fluorescent component exhibit a deuterium isotope effect. This result identifies it with the similar to 10 ps component, also lacking a deuterium isotope effect, observed id hypericin in transient absorption measurements monitoring stimulated emission. The clear and complementary observation in fluorescence of the similar to 10 ps component in both hypericin and hypocrellin A is a crucial link in refining a unified model of the hypericin and hypocrellin photophysics that we first proposed in J. Phys. Chem. B 1998, 102, 6098.
Combination of a Histological or Cytological Fixing Agent and One or More Photoactivatable Compounds of the Quinone Family, In Particular Hypericin, Hypocrellin A and Hypocrellin B
申请人:Peltier Eric
公开号:US20090047704A1
公开(公告)日:2009-02-19
The invention relates to the combination, in solution or in a kit, of a histological or cytological fixing solution and of one or more photoactivatable compounds of the family of quinones, in particular, hypericin, hypocrellin A and/or hypocrellin B. The invention also relates to a method for labeling cells or tissues by one or more photoactivatable compounds of the family of quinones, in which the cells or tissues in contact with a histological or cytological fixing solution are labeled, simultaneously or subsequently, by the photoactivatable compound(s) of the family of quinones.
PERYLENEQUINONE DERIVATIVES AND USES THEREOF
申请人:Sharma Sanjay K.
公开号:US20100047178A1
公开(公告)日:2010-02-25
The present invention relates to compounds which are perylenequinone derivatives, their stereoisomers and atropisomers. These compounds can be particularly useful as photosensitizers or sononsensitizers in photodynamic or sonodynamic therapy. The invention also relates to various methods for using these compounds in photodynamic and/or sonodynamic therapy. The compounds also are useful as therapeutic agents for treating various hyperproliferative disorders.